
|Articles|March 31, 2022
The Science Behind Using Circulating Tumor DNA for MCC
Author(s)Mary Scoviak, Managing Editor
In this second part of a 4 part video series, Lisa Zaba, MD, PhD, FAAD, explains the data behind the clinical trials on using circulating tumor DNA for merkel cell carcinoma (MCC). She expands on her talk from the 2022 American Academy of Dermatology Annual Meeting.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
How Emerging Androgenetic Alopecia Therapies Target DHT at the Scalp Level
2
Social Media Mythbusters: Beef Tallow
3
The Value of Clinician Collaboration for Skin Cancer Care
4
From Biopsy to Biomarkers: Experts Navigate Skin Cancer Diagnosis and Staging
5







